E1936. Somatostatin Receptor Imaging - Head to Toe: A Pictorial Review
  1. Shambo Guha Roy; Mercy Catholic Medical Center
  2. Shamim Shamim; All India Institute of Medical Sciences
  3. Ashokpraveen SL; All India Institute of Medical Sciences
Various tumors express somatostatin receptors (SSTR) that can be detected using molecular imaging techniques. Since the FDA granted approval, the use of Ga-68 labelled DOTATATE PET/CT for neuroendocrine tumors has gained popularity. Also, the approval of Lutathera for treatment of neuroendocrine tumors has ushered in a new therapeutic paradigm for SSTR-expressing tumors. Radiologists and nuclear medicine physicians should be aware of tumors that can be imaged using SSTR imaging agents and their subsequent clinical implication.

Educational Goals / Teaching Points
In this pictorial review we will review, most of the tumors that show SSTR expression and thus can be imaged with DOTATATE PET/CT. We will also discuss their advantages and disadvantages over other structural imaging and their clinical implications in patient management.

Key Anatomic/Physiologic Issues and Imaging Findings/Techniques
Somatostatin imaging agents, focusing on DOTATATE PET/CT, normal biodistribution and pitfalls, clinical implications for management and treatment, FDG vs DOTATATE, and use of Lutathera. Tumors expressing SSTR to be discussed are meningioma, head and neck paraganglioma (glomus tympanicum, jugulare, vagale and carotid body tumors), medullary thyroid cancer, bronchial carcinoid, gastroenteropancreatic neuroendocrine tumor, pheochromocytoma and paraganglioma, and neuroblastoma.

Availability of DOTATATE PET/CT is increasing. It has many advantages over structural imaging, not just for diagnosis, but also for therapeutic implication. This exhibit will summarize all the important SSTR-positive tumors radiologists should know about.